TNF Inhibitor denied as not medically necessary by Highmark?

Highmark uses Prime Therapeutics PBM. Adalimumab biosimilar preferred (Cyltezo/Hyrimoz/Yusimry). Step therapy through preferred biosimilar required for new starts; existing patients on Humira may grandfather.

Highmark Continuity of Care provisions — 90-day grandfather for established therapy. Cite Prime Therapeutics PA exception process. ACR 2019 Position Statement opposes non-medical switching of stable patients.

## Why Highmark May Deny a TNF Inhibitor for "Lack of Medical Necessity"

TNF inhibitors are FDA-approved for serious immune-mediated inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. A medical-necessity denial from Highmark means their clinical reviewer concluded that the submitted documentation did not sufficiently establish that the patient's condition meets Highmark's coverage criteria for biologic therapy. This is the most common denial reason for this drug class and is almost always documentation-driven rather than a reflection of whether the therapy is genuinely appropriate.

## Why This Denial Is Often Appealable

Medical-necessity denials frequently result from missing, vague, or disorganized records rather than a patient who truly does not qualify. A well-structured appeal that maps each of Highmark's stated criteria directly to specific chart entries — diagnosis confirmation, disease-severity measures, prior-treatment history, and prescriber judgment — reverses a substantial proportion of these denials. The prescriber's direct clinical assessment carries significant weight, particularly when supported by objective chart findings.

## Your Federal Appeal Rights

• Internal appeal: File within the deadline in the denial notice. Highmark must decide pre-service non-urgent appeals within 30 days; post-service within 60 days.
• External review (ACA §2719): If the internal appeal is denied, request binding IRO external review within approximately four months of the final denial. The IRO reviews the entire record de novo.
• Expedited review: If the standard timeline would seriously jeopardize your health, request expedited internal and external review simultaneously; decisions are typically within 72 hours.
• ERISA §503: Employer-plan members are entitled to a full-and-fair review, including access to all documents and clinical guidelines used by Highmark's reviewer.

## Documentation to Gather

1. Diagnosis confirmation — chart notes, lab results, imaging, or pathology establishing the precise diagnosis (with ICD code) that corresponds to an FDA-approved indication for this TNF inhibitor. 2. Disease-severity documentation — objective measures of disease activity from the clinical record, demonstrating that the condition meets the severity threshold described in Highmark's medical policy (obtain the policy from highmarkbcbs.com). 3. Prior-treatment history — a complete, dated list of previously tried therapies — medication names, dose adjustments, start/stop dates, and documented outcomes — showing the clinical course before biologic therapy was deemed necessary. 4. Prescriber medical-necessity letter — a letter from the treating specialist addressing each of Highmark's criteria explicitly, explaining the diagnosis, severity, prior-treatment failures, and clinical reasoning. 5. Specialist involvement — documentation confirming that the prescribing physician is an appropriate specialist (rheumatologist, gastroenterologist, dermatologist, etc.) as often required by Highmark's policy.

## Criteria-Mapping Strategy

Download the current version of Highmark's medical policy for TNF inhibitors for the relevant condition. Build a two-column table: left column lists each stated criterion verbatim; right column cites the specific page, date, and text from the medical record that satisfies it. Where Highmark's policy references the FDA-approved prescribing label, attach the relevant pages. Submit this structured table with the prescriber letter and medical records as a unified packet, so every requirement is addressed in one organized document.